A Phase IV, Single center, Open-label, Randomized Study to evaluate the Safety and Efficacy of a Tacrolimus twice daily, PROGRAF® versus a Tacrolimus Modified Release, ADVAGRAF®, in stable Liver transplant recipients taking Tacrolimus twice daily.
Phase of Trial: Phase IV
Latest Information Update: 31 Aug 2016
At a glance
- Drugs Tacrolimus (Primary)
- Indications Liver transplant rejection
- Focus Adverse reactions
- Acronyms SMART
- Sponsors Astellas Pharma
- 10 Apr 2015 Status changed from active, no longer recruiting to completed.
- 13 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register.
- 07 Aug 2012 New trial record